In a phase 3 study (SOLAR 1 trial), alpelisib plus fulvestrant were compared with placebo plus fulvestrant in patients with HR-positive and HER2-negative advanced breast cancer who had previously been treated with endocrine therapy. The gene discussed is ERBB2; the disease is breast cancer.